POSB16 Overall Survival Indirect Treatment Comparison Results Adjusted for Treatment Crossover: Brigatinib Relative to Alectinib in Patients with ALK+ NSCLC Previously Untreated with an ALK Inhibitor Using the Final Results from Alta-1L and Alex.
Saved in:
| Title: | POSB16 Overall Survival Indirect Treatment Comparison Results Adjusted for Treatment Crossover: Brigatinib Relative to Alectinib in Patients with ALK+ NSCLC Previously Untreated with an ALK Inhibitor Using the Final Results from Alta-1L and Alex. |
|---|---|
| Authors: | Cranmer, H1 (AUTHOR), Lin, HM2 (AUTHOR), Kay, S3 (AUTHOR), Cazzato, S4 (AUTHOR) |
| Source: | Value in Health. 2022 Supplement, Vol. 25 Issue 1, pS27-S27. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 10983015 |
|---|---|
| DOI: | 10.1016/j.jval.2021.11.126 |
